JP4480973B2 - Body fat reduction promoter - Google Patents
Body fat reduction promoter Download PDFInfo
- Publication number
- JP4480973B2 JP4480973B2 JP2003332049A JP2003332049A JP4480973B2 JP 4480973 B2 JP4480973 B2 JP 4480973B2 JP 2003332049 A JP2003332049 A JP 2003332049A JP 2003332049 A JP2003332049 A JP 2003332049A JP 4480973 B2 JP4480973 B2 JP 4480973B2
- Authority
- JP
- Japan
- Prior art keywords
- lotus
- body fat
- carnitine
- extract
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000000577 adipose tissue Anatomy 0.000 title claims description 27
- 240000002853 Nelumbo nucifera Species 0.000 claims description 58
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 57
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 57
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 29
- 239000000284 extract Substances 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 235000013361 beverage Nutrition 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000004130 lipolysis Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- -1 troches Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- 235000017471 coenzyme Q10 Nutrition 0.000 description 3
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 3
- 229940110767 coenzyme Q10 Drugs 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000337636 Kalama Species 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000005807 Nelumbo Nutrition 0.000 description 1
- 244000265736 Nelumbo pentapetala Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241001414989 Thysanoptera Species 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JXXCENBLGFBQJM-FYZOBXCZSA-N [(2r)-3-carboxy-2-hydroxypropyl]-trimethylazanium;chloride Chemical compound [Cl-].C[N+](C)(C)C[C@H](O)CC(O)=O JXXCENBLGFBQJM-FYZOBXCZSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明は、L−カルニチン及びハス胚芽の抽出物を含有することを特徴とする体脂肪の減少促進剤に関するものである。 The present invention relates to a body fat reduction promoter characterized by containing L-carnitine and a lotus germ extract.
体脂肪は、皮膚の下に蓄積される皮下脂肪及び内臓の周りに蓄積される内臓脂肪をいう。体脂肪の蓄積は、肥満だけでなく、糖尿病、高脂血症、高血圧症などの生活習慣病を引き起こす原因であり、深刻な問題となっている。従って、体脂肪を減少させることは、これらの疾患を予防及び治療する上で大変重要となる。 Body fat refers to subcutaneous fat that accumulates under the skin and visceral fat that accumulates around the viscera. Accumulation of body fat is a cause of not only obesity but also lifestyle-related diseases such as diabetes, hyperlipidemia and hypertension, and is a serious problem. Therefore, reducing body fat is very important in preventing and treating these diseases.
体脂肪を低下させるには、食事制限及び運動が有効とされているが、管理することは極めて難しい。一方、薬物により体脂肪を低下させる方法もあるが、安全性が問題となり、日常的に使用するのは好ましくない。交感神経興奮薬のエフェドリンは心停止の危険があり、食欲を抑制する作用のあるマジンドールやシブトラミンは、頭痛、口渇等の副作用を有する。そこで、日常的に連用可能で安全かつ十分な効果を示す体脂肪の減少促進剤が求められ、各方面で開発が行われてきた。 Dietary restriction and exercise are effective in reducing body fat, but it is extremely difficult to manage. On the other hand, there is a method of reducing body fat with a drug, but safety is a problem and it is not preferable to use it on a daily basis. The sympathomimetic drug ephedrine has a risk of cardiac arrest, and mazindol and sibutramine, which have an effect of suppressing appetite, have side effects such as headache and dry mouth. Therefore, a body fat reduction promoter that can be used on a daily basis and exhibits a safe and sufficient effect has been sought and has been developed in various fields.
例えば、ミカン科植物を有効成分とする脂肪分解促進剤(特許文献1参照)、アザミ族の植物を有効成分とする脂肪分解促進剤(特許文献2参照)、コショウ科植物を有効成分とする脂肪分解促進剤(特許文献3参照)、黄柏エキス及び黄連エキスからなる群から選択される少なくとも1種の成分を有効成分とする脂肪分解促進剤(特許文献4参照)、サンザシの果実成分を有効成分とする脂肪の燃焼を促進させる飲食品(特許文献5参照)、オレンジリーフ、オレンジフラワー、フキタンポポ葉及びカラマスルートの植物を有効成分とする脂肪分解促進剤(特許文献6参照)、構成アシル基中のω3系不飽和アシル基含量が15重量%以上であるジグリセリド及び/又はモノグリセリドを5重量%以上含有する油脂を有効成分とする体脂肪燃焼促進剤(特許文献7参照)などがある。しかし、それらの効果は十分なものではなかった。 For example, a lipolysis promoter containing a citrus plant as an active ingredient (see Patent Document 1), a lipolysis promoter containing a thrips plant as an active ingredient (see Patent Document 2), and a fat containing a pepper plant as an active ingredient Decomposition accelerator (see Patent Document 3), lipolysis accelerator (see Patent Document 4) containing at least one component selected from the group consisting of yellow cocoon extract and yellow continuous extract as an active ingredient, and effective hawthorn fruit component Food / beverage products that promote the burning of fat as ingredients (see Patent Document 5), lipolysis accelerators (see Patent Document 6), which comprise plants of orange leaf, orange flower, dandelion leaves and kalamas root as active ingredients, constituent acyl Body fat containing, as an active ingredient, an oil containing 5% by weight or more of diglyceride and / or monoglyceride having a ω3 unsaturated acyl group content of 15% by weight or more And the like baked accelerator (see patent document 7). However, their effects were not sufficient.
L−カルニチンは、脂肪酸をミトコンドリアに取り込み、エネルギーとする際の必須の物質である。L−カルニチンは脂質代謝に関わる物質であることから、従来より体脂肪を減少させる効果があるといわれてきたが、実際にはその効果は十分なものではない。また、ハス胚芽の抽出物は単独でコラーゲン産生促進効果、皮膚繊維芽細胞増殖促進効果(特許文献8)及び表皮代謝活性化効果(特許文献9)が報告されているが、体脂肪の減少効果については報告されていない。 L-carnitine is an indispensable substance when taking in fatty acids into mitochondria for energy. Since L-carnitine is a substance involved in lipid metabolism, it has hitherto been said to have an effect of reducing body fat, but the effect is not sufficient in practice. In addition, the lotus germ extract alone has been reported to have a collagen production promoting effect, a skin fibroblast proliferation promoting effect (Patent Document 8), and an epidermal metabolism activation effect (Patent Document 9). Has not been reported.
このような事情に鑑み、本発明者らはさらに優れた体脂肪の減少促進剤を得るべく鋭意検討を行った結果、L−カルニチン及びハス胚芽の抽出物を組み合わせることが、顕著な体脂肪の減少促進効果を発揮することを見出し、本発明を完成するに至った。 In view of such circumstances, the present inventors have intensively studied to obtain a further excellent body fat reduction promoter, and as a result, combining L-carnitine and lotus germ extract is a significant body fat. The inventors have found that a reduction promoting effect is exhibited, and have completed the present invention.
すなわち、本発明は、L−カルニチン及びハス胚芽の抽出物を含有することを特徴とする体脂肪の減少促進剤である。 That is, the present invention is a body fat reduction promoter characterized by containing L-carnitine and a lotus germ extract.
本発明のL−カルニチンは、体内において必須アミノ酸のリジン及びメチオニンから生合成される他、牛肉、豚肉、羊肉等に含まれており、日常的に摂取されている物質である。また、医薬品においては、塩化物であるL−塩化カルニチンの使用が認められており、安全性の高い成分とされている。本発明での使用にあたっては、化学的或いは酵素的に合成されたもの、微生物により産生されたもの、天然物から得られたもの等を用いることができる。又、L−カルニチンは塩の形であってもよい。L−カルニチンの塩にはナトリウム、カリウム、カルシウム、マグネシウム、亜鉛等の金属塩、アンモニウム、塩酸、硫酸、リン酸、酢酸、プロピオン酸、乳酸、酒石酸、クエン酸、コハク酸、マレイン酸等がある。これらは、単独で又は組み合わせて使用することができる。 The L-carnitine of the present invention is a substance that is not only biosynthesized from the essential amino acids lysine and methionine in the body but also contained in beef, pork, mutton, etc., and is ingested on a daily basis. In pharmaceuticals, the use of L-carnitine chloride, which is a chloride, is recognized and is considered a highly safe component. For use in the present invention, those synthesized chemically or enzymatically, those produced by microorganisms, those obtained from natural products, and the like can be used. L-carnitine may be in the form of a salt. Salts of L-carnitine include metal salts such as sodium, potassium, calcium, magnesium, zinc, ammonium, hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, succinic acid, maleic acid, etc. . These can be used alone or in combination.
本発明のハス胚芽は、平安時代以前からハス胚芽を含むハスの種がいわゆる「ハスの実」として食用されており、極めて安全性の高い食物である。本発明での使用にあたっては、ハス属のハス(Nelumbo nucifera Gaertn.)やキバナハス(N.lutea Pers.)、オニバス属のオニバス(Euyale ferox Salisb.)、オオオニバス属のオオオニバス(Victoria regiaLindl.)等の種の胚芽を使用することができる。生薬として流通するものとしては、蓮芯、蓮子芯、荷梗等が挙げられ、これらを購入して使用することもできる。ハスは、様々な部分が薬用として使われており、それぞれが異なった薬効を有している。例えば、ハス属のハス葉(荷葉)は下痢止め、止血に、果実(蓮肉)と雄しべ(蓮シュ)は強壮に、胚芽(蓮芯、蓮子芯、荷梗)は解熱にと異なった薬効が知られている。また、果実の成分としては多量のデンプンと糖類のラフィノースが知られているのに対し、葉にはロエメリン、ヌシフェリン等のアルカロイドが、そして、胚芽にはメチルコリパリン、ロツシン等の異なるアルカロイドが含まれていることが知られている。 The lotus germ of the present invention is an extremely safe food since the lotus seed containing the lotus germ has been edible as so-called “lotus seed” before the Heian period. For use in the present invention, a lotus of the genus Lotus (Nelumbo nuifera Gaertn.), N. lutea Pers. Seed germs can be used. Examples of products that are distributed as crude drugs include lotus wicks, lotus wicks, and cargo bells. These can be purchased and used. Various parts of lotus are used for medicinal purposes, and each has a different medicinal effect. For example, lotus leaves of lotus genus have anti-diarrhea, hemostasis, fruits (lotus meat) and stamens (lotus) are tonic, and germs (lotus wick, lotus wick, bunko) have different medicinal effects. It has been known. In addition, a large amount of starch and saccharide raffinose are known as fruit components, whereas leaves contain alkaloids such as loemerin and luciferin, and germs contain different alkaloids such as methyl coliparin and rotsin. It is known that
本発明におけるハス胚芽の抽出物は、ハスの種に含まれる胚芽を水もしくはメタノール、エタノール、プロパノール、アセトン等の親水性有機溶媒、又はこれらの混合溶媒で抽出することにより抽出液として得ることができる。又、当該抽出液を濃縮した濃縮液或いは乾燥した粉末の形態でも得ることができる。 The lotus germ extract in the present invention can be obtained as an extract by extracting the germ contained in the lotus seed with water or a hydrophilic organic solvent such as methanol, ethanol, propanol, acetone, or a mixed solvent thereof. it can. It can also be obtained in the form of a concentrated solution obtained by concentrating the extract or a dried powder.
本発明におけるハス胚芽の抽出物及びL−カルニチンの投与量或いは摂取量は、形態、症状、年齢、体重等によって異なるが、L−カルニチンは5〜5000mg/日、好ましくは50〜2000mg/日、より好ましくは100〜1000mg/日、ハス胚芽の抽出物は乾燥ハス胚芽に換算して0.1〜1000mg/日、好ましくは1〜500mg/日、より好ましくは10〜200mg/日である。 The dose or intake of the lotus germ extract and L-carnitine in the present invention varies depending on the form, symptoms, age, weight, etc., but L-carnitine is 5 to 5000 mg / day, preferably 50 to 2000 mg / day, More preferably, it is 100-1000 mg / day, and the lotus germ extract is 0.1-1000 mg / day, preferably 1-500 mg / day, more preferably 10-200 mg / day in terms of dry lotus germ.
本発明の体脂肪の減少促進剤は、医薬品又は食品として用いることができる。医薬品の形態としては、散剤、錠剤、顆粒剤、カプセル剤、トローチ剤、内服液剤、懸濁剤、シロップ剤等が挙げられる。食品の形態としては、上述の医薬品的な形態に加え、ビスケット、クッキー、キャンディー、チョコレート等の菓子、食酢、醤油、ドレッシング等の調味料、ハム、ベーコン、ソーセージ等の食肉製品、かまぼこ、はんぺい等の魚肉練り製品、果汁飲料、清涼飲料、アルコール飲料等の飲料、パン、麺、ジャム等にすることができる。これらの医薬品及び食品は、何れもL−カルニチンを5〜5000mg/日及びハス胚芽の抽出物を乾燥ハス胚芽に換算して0.1mg〜1000mg/日摂取できる形態であるが、摂取量を調整しやすい錠剤、顆粒剤、カプセル剤、トローチ剤、内服液剤及び飲料がより好ましい。又、医薬品及び食品の製造にあたっては、必要に応じて賦形剤、結合剤、滑沢剤、矯味剤、安定剤、ビタミン、ミネラル、香料等の医薬品及び食品の技術分野で通常使用されている補助剤を用いることができる。 The body fat reduction promoter of the present invention can be used as a pharmaceutical or a food. Examples of pharmaceutical forms include powders, tablets, granules, capsules, troches, liquids for internal use, suspensions, syrups and the like. As the form of food, in addition to the above-mentioned pharmaceutical form, confectionery such as biscuits, cookies, candy and chocolate, seasonings such as vinegar, soy sauce and dressing, meat products such as ham, bacon and sausage, kamaboko, rice It can be made into fish paste products such as pies, beverages such as fruit juice beverages, soft drinks, alcoholic beverages, bread, noodles, jams and the like. These medicines and foods can be ingested in an amount of 0.1 to 1000 mg / day in terms of L-carnitine 5 to 5000 mg / day and lotus germ extract converted to dried lotus germ, but the intake is adjusted Tablets, granules, capsules, troches, liquids for internal use, and beverages are more preferable. In the production of pharmaceuticals and foods, they are usually used in the technical fields of pharmaceuticals and foods such as excipients, binders, lubricants, flavoring agents, stabilizers, vitamins, minerals, and fragrances as necessary. Adjuvants can be used.
本発明のL−カルニチン及びハス胚芽の抽出物を含有することを特徴とする体脂肪の減少促進剤には、著しい体脂肪減少効果が認められた。 The body fat reduction promoter characterized by containing the extract of L-carnitine and lotus germ of the present invention has a significant body fat reduction effect.
次に、本発明を実施するための最良の形態として実施例を挙げるが、本発明はこれらに限定されるものではない。なお、実施例に示す(%)は重量(%)を示す。 Next, examples are given as the best mode for carrying out the present invention, but the present invention is not limited to these. In the examples, (%) indicates weight (%).
錠剤
<処方> 配合量(%)
1.L−カルニチン 10.0
2.ハス胚芽の乾燥水抽出物(等量の乾燥ハス胚芽に相当) 1.0
3.カフェイン 1.0
4.還元麦芽糖水飴 85.0
5.ショ糖脂肪酸エステル 3.0
<製造方法>
成分1〜4に70%エタノールを適量加えて練和し、押出し造粒した後に乾燥して顆粒を得る。成分5を加えて打錠成形し、500mgの錠剤を得る。当該錠剤を1日6錠摂取することで、L−カルニチンを300mg/日、乾燥ハス胚芽30mg/日に相当するハス胚芽の抽出物を摂取できる。
Tablet <Prescription> Compounding amount (%)
1. L-carnitine 10.0
2. Lotus water dry water extract (equivalent to an equal amount of dry lotus germ) 1.0
3. Caffeine 1.0
4). Reduced maltose starch syrup 85.0
5). Sucrose fatty acid ester 3.0
<Manufacturing method>
An appropriate amount of 70% ethanol is added to components 1 to 4, kneaded, extruded and granulated, and dried to obtain granules. Ingredient 5 is added and tableted to give 500 mg tablets. By taking 6 tablets per day, an extract of lotus germ corresponding to 300 mg / day of L-carnitine and 30 mg / day of dried lotus germ can be ingested.
トローチ剤
<処方> 配合量(%)
1.L−カルニチン 20.0
2.ハス胚芽の乾燥水抽出物(等量の乾燥ハス胚芽に相当) 5.0
3.乳糖 40.0
4.コーンスターチ 32.0
5.ショ糖脂肪酸エステル 3.0
<製造方法>
成分1〜4に70%エタノールを適量加えて練和して押出し造粒し、乾燥して顆粒を得る。成分5を加えて打錠成形し、1000mgのトローチ剤を得る。当該トローチ剤は、1日3個摂取することで、L−カルニチンを600mg/日、乾燥ハス胚芽150mg/日に相当するハス胚芽の抽出物を摂取できる。
Lozenges <Prescription> Formulation amount (%)
1. L-carnitine 20.0
2. Lotus water dry water extract (equivalent to an equal amount of dried lotus germ) 5.0
3. Lactose 40.0
4). Cornstarch 32.0
5). Sucrose fatty acid ester 3.0
<Manufacturing method>
An appropriate amount of 70% ethanol is added to components 1 to 4, kneaded, extruded and granulated, and dried to obtain granules. Ingredient 5 is added and tableted to obtain 1000 mg of lozenge. By taking 3 lozenges a day, it is possible to take an extract of lotus germ corresponding to 600 mg / day of L-carnitine and 150 mg / day of dried lotus germ.
顆粒剤
<処方> 配合量(%)
1.L−カルニチン 10.0
2.ハス胚芽の乾燥水抽出物(等量の乾燥ハス胚芽に相当) 2.0
3.還元麦芽糖水飴 30.0
4.セルロース 58.0
<製造方法>
成分1〜4に70%エタノールを適量加えて練和して押出し造粒し、乾燥して顆粒剤を得る。当該顆粒剤は、1回2000mgずつ1日3回摂取することで、L−カルニチンを600mg/日、乾燥ハス胚芽120mg/日に相当するハス胚芽の抽出物を摂取できる。
Granules <Prescription> Compounding amount (%)
1. L-carnitine 10.0
2. Lotus water dry water extract (equivalent to an equal amount of dried lotus germ) 2.0
3. Reduced maltose starch syrup 30.0
4). Cellulose 58.0
<Manufacturing method>
An appropriate amount of 70% ethanol is added to components 1 to 4, kneaded, extruded and granulated, and dried to obtain granules. The granule can ingest an extract of lotus germ corresponding to 600 mg / day of L-carnitine and 120 mg / day of dried lotus germ by ingesting 2000 mg at a time three times a day.
カプセル剤
<処方> 配合量(%)
1.L−カルニチン 10.0
2.ハス胚芽の乾燥エタノール抽出物(5倍量の乾燥ハス胚芽に相当) 2.0
3.コエンザイムQ10 0.2
4.セルロース 87.8
<製造方法>
成分1〜4を混合し、2号硬カプセルに250mg充填してカプセル剤を得る。当該カプセル剤は、1日6カプセル摂取することで、L−カルニチンを150mg/日、乾燥ハス胚芽150mg/日に相当するハス胚芽の抽出物を摂取できる。
Capsule <Prescription> Content (%)
1. L-carnitine 10.0
2. Lotus ethanol extract of dried lotus germ (equivalent to 5 times the amount of dried lotus germ) 2.0
3. Coenzyme Q10 0.2
4). Cellulose 87.8
<Manufacturing method>
Ingredients 1-4 are mixed and 250 mg is filled into No. 2 hard capsule to obtain a capsule. By taking 6 capsules per day, the capsule can take in an extract of lotus germ corresponding to 150 mg / day of L-carnitine and 150 mg / day of dried lotus germ.
飲料
<処方> 配合量(%)
1.L−カルニチン 1.0
2.ハス胚芽の30%エタノール抽出液(等量の乾燥ハス胚芽に相当) 0.5
3.10%コエンザイムQ10水溶液製剤 1.0
4.カフェイン 0.1
5.ショ糖 6.0
6.クエン酸 0.7
7.香料 適量
8.精製水で全量を100とする。
<製造方法>
成分8に成分1〜7を加え、撹拌溶解して濾過し、加熱殺菌して30mLガラス瓶に充填する。当該飲料は、1日1本摂取することでL−カルニチンを300mg/日、乾燥ハス胚芽150mg/日に相当するハス胚芽の抽出物を摂取できる。
Beverage <Prescription> Blending amount (%)
1. L-carnitine 1.0
2. 30% ethanol extract of lotus germ (equivalent to equivalent amount of dried lotus germ) 0.5
3. 10% Coenzyme Q10 aqueous solution formulation 1.0
4). Caffeine 0.1
5). Sucrose 6.0
6). Citric acid 0.7
7). Perfume appropriate amount 8. Bring the total amount to 100 with purified water.
<Manufacturing method>
Add ingredients 1-7 to ingredient 8, dissolve with stirring, filter, heat sterilize and fill into a 30 mL glass bottle. The beverage can ingest an extract of lotus germ corresponding to 300 mg / day of L-carnitine and 150 mg / day of dried lotus germ by ingesting once a day.
比較例
飲料
配合量(%)
<処方> 比較例1 比較例2 比較例3
1.L−カルニチン 0.0 1.0 0.0
2.ハス胚芽の30%エタノール抽出液 0.0 0.0 0.5
(等量の乾燥ハス胚芽に相当)
3.10%コエンザイムQ10水溶液製剤 1.0 1.0 1.0
4.カフェイン 0.1 0.1 0.1
5.ショ糖 6.0 6.0 6.0
6.クエン酸 0.7 0.7 0.7
7.香料 適量 適量 適量
8.精製水で全量を100とする。
<製造方法>
成分8に成分1〜7を加え、撹拌溶解して濾過し、加熱殺菌して30mLガラス瓶に充填する。
Comparative example Beverage
Compounding amount (%)
<Prescription> Comparative Example 1 Comparative Example 2 Comparative Example 3
1. L-carnitine 0.0 1.0 0.0
2. 30% ethanol extract of lotus germ 0.0 0.0 0.5
(Equivalent amount of dried lotus germ)
3. 10% Coenzyme Q10 aqueous solution formulation 1.0 1.0 1.0
4). Caffeine 0.1 0.1 0.1
5). Sucrose 6.0 6.0 6.0
6). Citric acid 0.7 0.7 0.7
7). Perfume appropriate amount appropriate amount appropriate amount Bring the total amount to 100 with purified water.
<Manufacturing method>
Add ingredients 1-7 to ingredient 8, dissolve with stirring, filter, heat sterilize and fill into a 30 mL glass bottle.
10週齢のWistar系雄性ラットを各群8匹ずつ4群に分け、表1記載の組成の食餌を2週間与えた。体脂肪率は小動物用体脂肪測定装置(EM−SCAN SA−2 セントラル科学貿易)で測定した。得られた結果を表2に示す。 Ten 10-week-old Wistar male rats were divided into 4 groups of 8 rats in each group, and a diet having the composition shown in Table 1 was given for 2 weeks. The body fat percentage was measured with a body fat measuring apparatus for small animals (EM-SCAN SA-2 Central Science Trade). The obtained results are shown in Table 2.
表2の結果より、L-カルニチン及びハス胚芽の抽出物を含まない食餌を与えた試験群1と比較して、L−カルニチンを含む食餌の試験群2及びハス胚芽の抽出物を含む食餌の試験群3における体脂肪率の減少はわずかである。一方、L−カルニチン及びハス胚芽の抽出物を含む食餌を与えた試験群4は、著しく体脂肪が低下していることがわかる。 From the results of Table 2, it can be seen that the test group 2 of the diet containing L-carnitine and the diet containing the extract of the lotus germ were compared with the test group 1 given the diet not containing the extract of L-carnitine and the lotus germ. The decrease in body fat percentage in test group 3 is slight. On the other hand, it can be seen that the test group 4 fed the diet containing the extract of L-carnitine and the lotus germ significantly reduced body fat.
25〜40歳の健常男性3名及び女性2名(A、B、C、D、E)に、食生活を変えることなく、実施例5の飲料を1日1本8週間摂取させ、BMI〔Body Mass Index:体重kg/(身長m×身長m)〕、体脂肪率、ウエストサイズを測定した。結果を表4に示す。 Three healthy men aged 25 to 40 and two women (A, B, C, D, E) were allowed to consume the beverage of Example 5 once a day for 8 weeks without changing their diet, and BMI [ Body Mass Index: body weight kg / (height m × height m)], body fat percentage, and waist size were measured. The results are shown in Table 4.
表3の結果より、本発明の体脂肪の減少促進剤を摂取すると、食生活を変えることなく、体脂肪率が減少し、それに伴いBMI、ウエストサイズが低下していることがわかる。 From the results in Table 3, it can be seen that when the body fat reduction promoter of the present invention is ingested, the body fat percentage decreases without changing the diet, and accordingly, BMI and waist size decrease.
L−カルニチン及びハス胚芽の抽出物を含有する体脂肪の減少促進剤は、過度の体脂肪が起因となる生活習慣病の予防及び治療にも適用できる。
The body fat reduction promoter containing L-carnitine and lotus germ extract can also be applied to the prevention and treatment of lifestyle-related diseases caused by excessive body fat.
Claims (2)
The body fat reduction promoter according to claim 1, wherein L-carnitine is in a form that can be ingested in an amount of 5-5000 mg / day and a lotus germ extract converted to dried lotus germ in an amount of 0.1-1000 mg / day.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003332049A JP4480973B2 (en) | 2003-09-24 | 2003-09-24 | Body fat reduction promoter |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003332049A JP4480973B2 (en) | 2003-09-24 | 2003-09-24 | Body fat reduction promoter |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005097159A JP2005097159A (en) | 2005-04-14 |
JP4480973B2 true JP4480973B2 (en) | 2010-06-16 |
Family
ID=34460517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003332049A Expired - Lifetime JP4480973B2 (en) | 2003-09-24 | 2003-09-24 | Body fat reduction promoter |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4480973B2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0606864D0 (en) * | 2006-04-05 | 2006-05-17 | Univ Nottingham | Increades fatty acid oxidation |
JP5819209B2 (en) * | 2012-01-24 | 2015-11-18 | 日本メナード化粧品株式会社 | Differentiation promoter from stem cells to brown adipocytes |
JP2018100247A (en) * | 2016-12-21 | 2018-06-28 | 松浦薬業株式会社 | Dextrin formulation |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11310531A (en) * | 1998-04-28 | 1999-11-09 | Asahi Breweries Ltd | Fat decomposition promoter with higenamine as active ingredient |
-
2003
- 2003-09-24 JP JP2003332049A patent/JP4480973B2/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11310531A (en) * | 1998-04-28 | 1999-11-09 | Asahi Breweries Ltd | Fat decomposition promoter with higenamine as active ingredient |
Also Published As
Publication number | Publication date |
---|---|
JP2005097159A (en) | 2005-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010202520A (en) | Skin improver and oral composition for cosmetic and health purposes | |
WO2002055074A1 (en) | Preventives or remedies for arthritis | |
KR20140021598A (en) | Composition, glucose metabolism-improving agent, and method for improving glucose metabolism | |
JP5066670B2 (en) | Anti-obesity agent and edible composition | |
JP5053535B2 (en) | Oral for improving sleep or waking up | |
JP5749880B2 (en) | Body fat accumulation improving agent and metabolic syndrome improving agent comprising D-tagatose as an active ingredient | |
JP6222663B2 (en) | Muscle atrophy inhibitor | |
WO2015137387A1 (en) | Muscle enhancing drug | |
JP2008143811A (en) | Lipid metabolism promoting composition | |
JP4480973B2 (en) | Body fat reduction promoter | |
JP5710091B2 (en) | NO production promoter | |
JP2009155334A (en) | Medicine | |
JP2007099653A (en) | Arthrodynia ameliorator | |
JP2009107987A (en) | Muscle enhancer | |
JP6143294B2 (en) | Muscle glycogen accumulation promoter during muscle glycogen recovery, food and drink for muscle glycogen accumulation promotion during muscle glycogen recovery, and method for producing muscle glycogen accumulation promoter during muscle glycogen recovery | |
KR101782132B1 (en) | Health care food of composition comprising the extract material in Ginkgo biloba and Plantago ovata | |
JP4915959B2 (en) | Novel sweetener with sugar-like taste, production method and use thereof | |
JP2003286180A (en) | Obesity inhibitor and food containing the same | |
US20070093554A1 (en) | Agent for improving feeling of cold | |
KR102245628B1 (en) | Composition for internal use | |
JP2013124222A (en) | Visceral fat reducing agent | |
JPH069419A (en) | Method for improving taste of essence of pine and oral ingesta obtained by the same method | |
KR20120040890A (en) | Blueberry fermentation extract as an effective components for prevention and treatment of obesity | |
JP2003012527A (en) | Hyperphagia inhibitor | |
JP2006137730A (en) | Anti-fatigue agent or stamina enhancing agent, functional food or cosmetic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060718 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100105 |
|
TRDD | Decision of grant or rejection written | ||
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100215 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100316 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100317 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130326 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4480973 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140326 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |